American Biotech Innovation Alliance urges Congress to prioritize US leadership in biopharma

The American Biotech Innovation Alliance, formed in May, appeared on Capitol Hill on September 30, 2026 to address lawmakers.

The group argued that maintaining U.S. dominance in biopharma requires focused policy support, investment, and regulatory frameworks.

Alliance leaders, including Promontory Therapeutics COO Matthew Price, called for specific actions such as increased funding for biotech research and streamlined approval processes.

The alliance positioned itself as a trade organization representing emerging biotech firms, seeking to influence upcoming legislation.